Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Deep Learning In Drug Discovery And Diagnostics Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for artificial intelligence in drug discovery has experienced rapid expansion over recent years. Forecasts indicate an increase from $2.33 billion in 2025 to $2.93 billion in 2026, representing a compound annual growth rate (CAGR) of 25.9%. This historic growth has been driven by several factors, including higher pharmaceutical R&D expenditures, the mounting complexity of drug discovery workflows, greater accessibility to biological and chemical data, an early embrace of machine learning within bioinformatics, and a rise in partnerships between pharmaceutical companies and technology firms.

The market for artificial intelligence in drug discovery is projected to experience remarkable expansion over the coming years. Its value is anticipated to reach $7.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 26.2%. This growth during the forecast period is fueled by factors such as the rising utilization of generative AI models, increased need for precision therapies, the broadening of clinical trial designs enabled by AI, greater investment in cloud-based discovery platforms, and growing regulatory endorsement of AI-supported drug development. Key trends shaping this period include the heightened application of AI for target identification, the growing use of deep learning in molecule screening, the wider implementation of virtual drug screening platforms, the advancement of AI-based lead optimization technologies, and a stronger emphasis on shortening drug development timelines.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19394&type=smp

Deep Learning In Drug Discovery And Diagnostics Market Demand Drivers: What Is Fueling Industry Growth?

The increasing need for customized treatments is anticipated to boost the expansion of artificial intelligence within the drug discovery sector in the coming years. Personalized medicine is a focused strategy for preventing, diagnosing, and treating diseases by utilizing a person’s genetic, proteomic, or biological information to inform clinical choices. Its rising popularity stems from a greater demand for precise, patient-specific therapies that enhance treatment results while minimizing side effects. AI facilitates this trend by speeding up the identification of molecular targets, refining drug candidates, and improving clinical decision-making along the entire development process. As an example, the Personalized Medicine Coalition, a research and advocacy group based in the United States, reported in February 2024 that the U.S. FDA approved 26 new personalized therapies in 2023—these comprised 20 new molecular entities and 6 gene- or cell-based therapies. Consequently, the rising demand for personalized medicine is fueling the growth of artificial intelligence in the drug discovery market.

Deep Learning In Drug Discovery And Diagnostics Market Segment Analysis Highlighting Growth Areas

The artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning

2) By Drug Type: Small Molecules, Large Molecules

3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics

4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems

2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis

3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications

Deep Learning In Drug Discovery And Diagnostics Market Innovation Trends: Which Developments Are Transforming The Industry?

Major corporations are channeling funds into businesses that specialize in using artificial intelligence within the drug discovery sector, aiming to identify and create novel therapies while making these models accessible to other pharmaceutical developers. Such strategic financial commitments can supply the necessary capital for research and development of new drugs, a process that is often both expensive and drawn out. This infusion of money enables companies to push forward their drug discovery initiatives and introduce fresh treatments to the marketplace. A case in point occurred in July 2023 when Nvidia, a software company headquartered in the United States, injected $50 million into Recursion Pharmaceuticals, a US-based biotechnology enterprise that leverages AI for drug discovery. This investment is intended to accelerate Recursion’s development of its AI foundation models for biology and chemistry through the utilization of Nvidia’s cloud-based services.

Deep Learning In Drug Discovery And Diagnostics Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.

Access The Complete Deep Learning In Drug Discovery And Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/deep-learning-in-drug-discovery-and-diagnostics-global-market-report

Deep Learning In Drug Discovery And Diagnostics Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Deep Learning In Drug Discovery And Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=28922&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model